The estimated Net Worth of Reid G. Adler is at least $1.05 Milion dollars as of 17 August 2022. Reid Adler owns over 300,000 units of Vistagen Therapeutics stock worth over $1,054,081 and over the last 3 years Reid sold VTGN stock worth over $0.
Reid has made over 1 trades of the Vistagen Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently Reid bought 300,000 units of VTGN stock worth $51,000 on 17 August 2022.
The largest trade Reid's ever made was buying 300,000 units of Vistagen Therapeutics stock on 17 August 2022 worth over $51,000. On average, Reid trades about 50,000 units every 0 days since 2022. As of 17 August 2022 Reid still owns at least 334,629 units of Vistagen Therapeutics stock.
You can see the complete history of Reid Adler stock trades at the bottom of the page.
Reid's mailing address filed with the SEC is C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVENUE, SOUTH SAN FRANCISCO, CA, 94080.
Over the last 8 years, insiders at Vistagen Therapeutics have traded over $147,300 worth of Vistagen Therapeutics stock and bought 1,944,506 units worth $18,208,989 . The most active insiders traders include Healthcare Capital Partners..., Capital Lp Commodore oraz Jon S Saxe. On average, Vistagen Therapeutics executives and independent directors trade stock every 88 days with the average trade being worth of $378,372. The most recent stock trade was executed by Capital Lp Commodore on 7 August 2023, trading 775,756 units of VTGN stock currently worth $17,958,751.
we have developed a versatile stem cell technology platform based on the controlled differentiation of human pluripotent stem cells into mature, non-transformed, human cells which can be used to create novel bioassay systems for predictive toxicology, drug metabolism screening, drug discovery, drug rescue and cell therapy. we believe our stem cell technology platform, human clinical trials in a test tube™, can provide clinically relevant predictions of potential toxicity and metabolism issues of promising new drug candidates long before they are ever tested in humans.
Vistagen Therapeutics executives and other stock owners filed with the SEC include: